Firm acknowledged for its means to watch remedy response with its Signatera™ MRD check
AUSTIN, Texas, March 28, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a world chief in cell-free DNA testing, has been named to Quick Firm’s annual listing of the World’s Most Innovative Companies for 2022.
Natera ranked sixth within the Health class and was acknowledged for its personalised and tumor-informed molecular residual illness (MRD) check, Signatera, and its means to watch immunotherapy response. Two main research1,2 have demonstrated Signatera’s means to foretell which sufferers, throughout a broad vary of most cancers varieties, are more than likely to learn from immunotherapy. As of November 2021, Medicare covers the serial use of Signatera for pan-cancer immunotherapy monitoring.
“This recognition is a testomony to the influence Signatera has made on the lives of individuals residing with most cancers and our pursuit to rework most cancers care with personalised MRD testing,” stated Steve Chapman, CEO of Natera. “We stay steadfast in our dedication to growing progressive services and products that assist inform individuals about their well being and are honored to have made this prestigious listing.”
The World’s Most Revolutionary Firms is Quick Firm’s signature franchise and one in every of its most extremely anticipated editorial efforts annually, offering each a snapshot and a highway map for the way forward for innovation throughout essentially the most dynamic sectors of the financial system.
Natera™ is a world chief in cell-free DNA testing, devoted to oncology, girls’s well being, and organ well being. We purpose to make personalised genetic testing and diagnostics a part of the usual of care to guard well being, and inform earlier, extra focused interventions that assist result in longer, more healthy lives. Natera’s checks are validated by greater than 100 peer-reviewed publications that show excessive accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories licensed underneath the Scientific Laboratory Enchancment Amendments (CLIA) in Austin, Texas and San Carlos, California. For extra data, go to www.natera.com.
About Quick Firm
Quick Firm is the one media model absolutely devoted to the important intersection of enterprise, innovation, and design, participating essentially the most influential leaders, corporations, and thinkers on the way forward for enterprise. Headquartered in New York Metropolis, Quick Firm is printed by Mansueto Ventures LLC, together with our sister publication Inc., and could be discovered on-line at www.fastcompany.com.
All statements apart from statements of historic details contained on this press launch are forward-looking statements and aren’t a illustration that Natera’s plans, estimates, or expectations will likely be achieved. These forward-looking statements symbolize Natera’s expectations as of the date of this press launch, and Natera disclaims any obligation to replace the forward-looking statements. These forward-looking statements are topic to recognized and unknown dangers and uncertainties which will trigger precise outcomes to vary materially, together with with respect to our efforts to develop and commercialize new product choices, whether or not the outcomes of scientific or different research will assist using our product choices, the influence of outcomes of such research, our expectations of the reliability, accuracy and efficiency of our checks, or of the advantages of our checks and product choices to sufferers, suppliers and payers. Further dangers and uncertainties are mentioned in better element in “Threat Elements” in Natera’s current filings on Kinds 10-Ok and 10-Q and in different filings Natera makes with the SEC every so often. These paperwork can be found at www.natera.com/investors and www.sec.gov.
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Kate Stabrawa, Communications, Natera, Inc., [email protected]
- Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432-437.
- Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalised circulating tumor DNA evaluation as a predictive biomarker in stable tumor sufferers handled with pembrolizumab. Nat Most cancers. 2020;1(9):873-881.
SOURCE Natera, Inc.